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ABSTRACT 36 
Factors contributing to incomplete drug release from a number of mesoporous silica 37 
formulations are not well understood. This study aims to address this gap in knowledge by 38 
exploring the role of drug adsorption onto silica substrates during the drug release process in 39 
dissolution media. Adsorption isotherms were generated to understand drug adsorption 40 
behaviour onto the silica surface. Two silica materials were selected (SBA-15 (mesoporous) 41 
and Aerosil®200 (non-porous)) to investigate the influence of porous architecture on the 42 
adsorption/dissolution processes. The ability of the dissolution medium to wet the silica 43 
surface, particularly the porous network, was investigated by the addition of a surfactant to 44 
the dissolution medium. The results demonstrated that a larger amount of drug was bound/m
2
 45 
to the non-porous surface than to the mesoporous material. Adsorption isotherms proved 46 
useful in understanding drug adsorption/release behaviour for the non-porous silica 47 
formulation. However, the quantity of drug remaining on the mesoporous silica surface after 48 
dissolution was significantly higher than the amount predicted using adsorption isotherm 49 
data. These results suggest that a fraction of loaded drug molecules were tightly bound to the 50 
silica surface or attached to sites which are inaccessible for the dissolution media. The 51 
presence of surfactant, sodium dodecyl sulphate, in the media enhanced drug release from the 52 
silica surface. This behaviour can be attributed to both the improved wetting characteristics of 53 
the media and adsorption of the surfactant to the silica surface. The findings of this study 54 
reinforce the significance of the role that silica porous architecture plays in the dissolution 55 
process and indicates that accessible surface area is an important parameter to consider for 56 
mesoporous systems in relation to drug release.  57 
KEYWORDS 58 
Adsorption; isotherm; dissolution; mesoporous silica; surfactant; porous architecture 59 
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1. INTRODUCTION 60 
Loading drugs onto mesoporous silica materials has been considered as a formulation 61 
strategy to improve the aqueous solubility of BCS Class II drugs 
1-3
. The high surface area 62 
and large pore volume of these silica carriers render them attractive substrates for enhancing 63 
drug dissolution 
4
. Drug molecules loaded onto the silica surface exist in a stabilised 64 
amorphous state which greatly enhances drug solubility and dissolution rate 
5-7
. In recent 65 
years, research in this area has focused on the development of various drug loading methods 66 
for these carriers 
8-10
 and the first in vivo animal studies have been conducted 
11-13
. However, 67 
there remains a gap in knowledge as regards understanding the mechanism of drug 68 
dissolution from mesoporous silica formulations  
3
. Incomplete in vitro drug release from 69 
these systems has been reported by many groups in the literature 
9, 14, 15
. However, the factors 70 
contributing to these observations in dissolution experiments, performed under sink 71 
conditions, are not well understood. A study by Bui et al explored the use of mesoporous 72 
silica materials as adsorbents for chemicals found in pharmaceutical wastewater 
16
. They 73 
determined that some drug molecules could bind irreversibly onto the silica surface. 74 
However, the impact of irreversible drug binding on the release of drug from mesoporous 75 
silica formulations has not been considered in the literature to date.  76 
The aim of this study was to elucidate the role of drug adsorption onto porous and non-porous 77 
silica substrates, during drug release from these systems. Adsorption isotherms were 78 
generated to understand drug adsorption onto the silica surface. This equilibrium process 79 
describing drug bound to the silica surface and drug existing in solution emerged as a 80 
significant factor in gentamicin release from a silica carrier in a study by Xue et al 
17
. In this 81 
work, sulphamethazine (SZ) was chosen as the model drug. Sulphamethazine has the 82 
potential to form amine-hydroxyl hydrogen bonds with the silica surface 
17
. Two silica 83 
substrates were selected (SBA-15 (mesoporous) and Aerosil®200 (non-porous)) to investigate 84 
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the influence of porous architecture on the adsorption process. The extent of passive drug 85 
adsorption was quantified and compared with drug retained during dissolution experiments to 86 
determine whether isotherms can predict the extent of drug release from these formulations.  87 
The ability of the dissolution medium to influence drug adsorption and release was 88 
considered through the addition of a surfactant to the dissolution medium. Sodium dodecyl 89 
sulphate (SDS), an anionic surfactant, was chosen as it is a common excipient added to 90 
dissolution media and formulations to improve the wetting characteristics and the 91 
solubilisation of drug molecules 
18
. Sulphamethazine dissolution from SZ/silica systems in 92 
0.1M HCl media was compared with drug dissolution in media containing surfactant to 93 
determine if improved dissolution media wetting capability enhances drug release from silica 94 
systems.  95 
 96 
 97 
 98 
 99 
 100 
 101 
 102 
 103 
 104 
 105 
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2. EXPERIMENTAL SECTION 107 
2.1. Materials 108 
SBA-15 was obtained from Glantreo Ltd. (Ireland). Aerosil
®
200 Pharma was sourced from 109 
Evonik Industries (Germany). Silica surface and pore properties were obtained from suppliers 110 
(Table 1). Sulphamethazine (SZ) and sodium dodecyl sulphate (SDS) (>98.5%) were 111 
purchased from Sigma Aldrich (Ireland). Liquid carbon dioxide was supplied by Irish 112 
Oxygen Ltd (Ireland). All other chemicals and solvents were of analytical grade or HPLC 113 
grade and purchased from Sigma-Aldrich (Ireland).  114 
Table 1. Properties of silica materials obtained from suppliers  115 
Silica Material Porosity Particle Size 
(µm) 
Surface Area 
(m2) 
Pore Volume 
(cm3) 
Pore Diameter 
(Å) 
SBA-15 Mesoporous 30 678.57 ± 8.23 0.64 ± 0.02 51.85 ± 0.05 
Aerosil
®
200 Non-porous 12 200.00 ± 25.00 N/A N/A 
 116 
2.2. Surface Tension Measurements  117 
Surface tension was determined experimentally using a KRUSS processor tensiometer K12 118 
(KRUSS GmbH, Germany) with a platinum Wilhelmy plate. The plate was washed with 119 
deionised water, followed by an ethanol wash and subsequently flamed over a Bunsen burner 120 
after each measurement. All measurements were performed at 37 
o
C which was maintained 121 
with the HAAKE water bath (Thermo Fisher Scientific Inc., USA). Full independent 122 
replicates were performed in triplicate. Critical micellar concentrations (CMC) of SDS in 123 
deionised water and 0.1M HCl were determined by analysing changes in surface tension over 124 
the surfactant concentration range investigated. 125 
 126 
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2.3. Solubility Measurements 127 
Solubility studies were performed in triplicate by the addition of excess sulphamethazine 128 
(SZ) to 10 ml of buffer media (0.1M HCl) using a standardised shake-flask method with a 129 
total shaking time of 48 h at 37
o
C. Samples (2 ml volume) were removed at 24 h and 48 h 130 
time points and centrifuged at 16,500g for 13 min using a Hermle z233M-2 fixed angle rotor 131 
centrifuge, (HERMLE Labortechnik GmbH, Germany). The supernatant was removed and 132 
centrifuged again under the same conditions. The resultant supernatant was analysed using 133 
HPLC following dilution with mobile phase.  134 
2.4. Adsorption Studies 135 
Sulphamethazine adsorption studies were performed in screw-capped glass vials containing 136 
100 mg of silica (SBA-15 or Aerosil®200) in 20 ml of SZ solution at a defined concentration 137 
in buffer (0.1 M HCl, pH 1.2). Experiments were conducted under the same conditions as 138 
solubility measurements i.e. shake-flask conditions for 24 h at 37 
o
C. At 24 h, samples (2 ml) 139 
volume were removed and centrifuged at 16,500 g for 13 min using a Hermle z233M-2 fixed 140 
angle rotor centrifuge, (HERMLE Labortechnik GmbH, Germany). The supernatant was 141 
removed and centrifuged again under the same conditions. The resultant supernatant was 142 
analysed using HPLC following dilution with mobile phase.  143 
Adsorption studies were also conducted under the same conditions in the presence of a 144 
surfactant (sodium dodecyl sulphate (SDS)) at two defined concentrations, 10 mM SDS and 145 
50 mM SDS. These concentrations were chosen as they reflect the range of concentrations 146 
approved for SDS by the U.S. Food and Drug Administration (FDA) Dissolution Methods 
19
. 147 
An isotherm was generated by plotting the concentration of drug (mM) in solution at 24 h (x-148 
axis) versus the quantity of drug adsorbed (mmol) per gram or per m
2 
of the silica carrier (y-149 
Page 8 of 33
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
9 
 
axis). Linearised forms of the Langmuir 
20
 and Freundlich 
21
 isotherms were applied to the 150 
experimental data and the parameters determined are detailed in Table 2. 151 
Table 2. Linearized forms of Langmuir and Freundlich Isotherms 152 
Name Linearised Form Plot Parameters 
Langmuir 
/	 = 	 (1/. 
) 	+ 	/
 
F versus F/B 
a = slope/intercept 
Nt 
 
= 1/slope 
Freundlich 	 = 		 + 	 logF versus log B 
a = intercept 
m = slope 
where B is the concentration of drug adsorbed to the silica surface, F is the concentration of 153 
free substrate in solution at 24 h, Nt is the total number of binding sites and a is related to the 154 
average binding affinity 155 
2.5. Preparation of Sulphamethazine Loaded Silica Formulations 156 
Sulphamethazine loaded silica formulations were prepared according to the method 157 
previously described by Ahern et al 
15
. The drug and silica material was combined at a ratio 158 
of 1 mg SZ: 3 m
2
 silica (SBA-15 or Aerosil®200) in a BC 316 high-pressure reactor (High 159 
Pressure Equipment Company, USA) and stirred using a magnetic stirring. The reactor was 160 
heated to 40 °C using heating tape and maintained at this temperature for the duration of the 161 
experiment. Temperature was monitored using a temperature monitor (Horst GmbH, 162 
Germany). The reactor cell was filled with liquid CO2 and a high pressure pump (D Series 163 
Syringe Pump 260D, Teledyne ISCO, USA) was used to pump additional CO2 to a final 164 
processing pressure (27.58 MPa). After 24 h, the cell was depressurised rapidly by venting 165 
the CO2. The processed material was collected from the cell and stored in a desiccator prior 166 
to analysis. 167 
 168 
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 169 
2.6. Drug Content Quantification 170 
The sulphamethazine content of the silica formulations were determined by 171 
thermogravimetric analysis (TGA), using a TGA 500 instrument (TA Instruments Ltd., 172 
United Kingdom). Samples in the weight range 2–10 mg were loaded onto tared platinum 173 
pans and heated from ambient temperature to 900 °C, at a heating rate of 10 °C/min under an 174 
inert N2 atmosphere. Samples were analysed in triplicate. The drug quantity was calculated 175 
based on the weight loss between 100 and 900 °C, corrected for the weight loss over the same 176 
temperature range for a silica reference sample 
14
. TGA thermograms were analysed using 177 
Universal Analysis 2000 software (TA Instruments Ltd., United Kingdom). Drug-loading 178 
efficiency was calculated using Equation 1:  179 
			(%) =
 !"	#$ %	"&!#'(%	()%)
*+,&$,'!"	#$ %	"&!#'(%	()%)
	∗ 100    Equation 1 180 
The theoretical drug-loading was based on mass fraction of drug and silica used to prepare 181 
samples. 182 
2.7. Dissolution Studies 183 
Dissolution studies were performed in triplicate using USP II apparatus (Erweka® DT600 184 
dissolution test system (ERWEKA GmBH, Germany)) in 500ml buffer (0.1M HCl, pH 1.2) 185 
at 37 ± 5oC at a paddle rotation of 75 rpm. Sink conditions were employed for all dissolution 186 
experiments. A fixed mass of unprocessed drug (150 mg) or a mass of drug-silica formulation 187 
equivalent to 150 mg of drug was added to the dissolution medium. Samples of 4 ml volume 188 
were withdrawn at 1, 5, 10, 15, 30, 60 and 120 min intervals with an additional sample taken 189 
at the 24 h time point. Samples were immediately replaced with an equal volume of fresh, 190 
pre-warmed medium. The withdrawn samples were centrifuged at 16,500 g for 13 min using 191 
a Hermle z233M-2 fixed angle rotor centrifuge, (HERMLE Labortechnik GmbH, Germany). 192 
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The supernatant was removed and centrifuged again under the same conditions. The resultant 193 
supernatant was analysed using HPLC following dilution with mobile phase.  194 
Dissolution studies were repeated as above with the addition of surfactant (SDS) to the 195 
dissolution media at two concentrations (10 mM and 50 mM).  196 
2.8. HPLC Analysis of Sulphamethazine and Sodium Dodecyl Sulphate 197 
Reversed phase high performance liquid chromatography (HPLC) was performed using an 198 
Agilent 1200 series HPLC system (Agilent Technologies, USA) equipped with both a Photo 199 
Diode Array Detector (DAD) and an Evaporative Light Scattering Detector (ELSD) in series. 200 
To quantify drug content in adsorption and dissolution studies without surfactant a reversed-201 
phase column Kinetex C-18 column (150 mm × 4 mm) with internal pore width 2.6 µm 202 
(Phenomenex Ltd., United Kingdom) was utilised. An isocratic HPLC-DAD (diode array 203 
detector) technique adapted from a method by Ding et al 
22
 with a mobile phase consisting of 204 
acetonitrile – water – acetic acid (25:75:0.05), an injection volume of 50 µL and a flow rate 205 
of 1 ml.min
-1
 at ambient temperature was employed. The detection wavelength was 265 nm. 206 
The retention time for sulphamethazine was 5.9 min.  207 
To quantify both drug and surfactant concentrations in adsorption and dissolution studies, a 208 
HPLC-ELSD method adapted from Im et al 
23
 was utilised. The ELSD system was operated 209 
with an evaporative temperature of 80
o
C, a nebulizer temperature of 70 
o
C and a N2 gas flow 210 
rate of 1.0 L.min
-1
. A reversed-phase column Prodigy ODS-3 column (150 mm × 4.6 mm) 211 
with internal pore width 5 µm (Phenomenex Ltd., United Kingdom) was utilised. Drug and 212 
surfactant were separated using a mobile phase gradient which consisted of two solutions: 213 
eluent A (water (25 mM ammonium acetate)) and B (acetonitrile). The gradient program 214 
started with 5% eluent B for 2 min, followed a 6 min gradient up to 95% eluent B. The 215 
column was then equilibrated with starting conditions for 2 min before the next injection. The 216 
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flow rate was 1ml.min
-1 
with an injection volume of 10 µL. Column temperature was set to 217 
30
o
C. The retention time for sulphamethazine and sodium dodecyl sulphate was 5.9 min and 218 
7.4 min, respectively.  219 
2.9. Pore size analysis of Mesoporous Silica Systems Before and After Dissolution  220 
Pore size analysis by nitrogen (N2) adsorption of the mesoporous sulphamethazine-SBA-15 221 
formulation was carried out using a Gemini VI surface area and pore size analyser 222 
(Micromeritics, USA). Aerosil®200 is a non-porous silica material so porosity analysis was 223 
not undertaken. The samples were degassed overnight at 100 °C in a FlowPrep 060 sample 224 
degas system (Micromeritics, USA) prior to analysis. During analysis, liquid N2 at −196 °C 225 
maintained isothermal conditions. The mesopore volume along with mesopore width were 226 
calculated using the Barrett–Joyner–Halenda (BJH) adsorption correlation 
24
. Samples were 227 
analysed in duplicate. 228 
2.10. Statistical Analysis 229 
All statistical analyses were conducted using Microsoft Excel 2013 (Microsoft, USA) and 230 
GraphPad Prism (ver. 5, GraphPad Software Inc., USA). Results are expressed as mean ± 231 
standard deviation. In vitro dissolution and adsorption isotherm data comparing both 232 
formulations at different time points and concentrations respectively were tested for 233 
significance using a two-tailed, independent sample t-test, assuming Gaussian distribution 234 
and equal variance (p < 0.05 was considered significant).  235 
 236 
  237 
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3. RESULTS 238 
3.1. Sulphamethazine (SZ) Loading Efficiency 239 
Sulphamethazine was loaded onto both silica substrates at a theoretical ratio of 1 mg SZ/ 3 m
2
 240 
silica surface area. Sulphamethazine loading onto SBA-15 was 190 mg/g silica corresponding 241 
to a drug loading efficiency of 75.86% (calculated using Equation 1). SZ drug loading onto 242 
Aerosil®200 was 60 mg/g silica, equivalent to an 88.62% loading efficiency. These results are 243 
in line with loading efficiencies previously reported using SC-CO2 methods 
15
.   244 
3.2. Solubility Studies 245 
SDS increases the solubility of some drugs above its CMC (critical micellar concentration) 
25
. 246 
In this study, the CMC of SDS in both deionised water and 0.1M HCl were determined.  The 247 
CMC of SDS in deionised water at 37
o
C was 7.3 mM (0.21% w/v), while in 0.1 M HCl 248 
solution at 37
o
C it was 0.8 mM (0.023%). Therefore, both concentrations of surfactant 249 
investigated in this study (0.3% w/v and 1.44% w/v) were above the CMC in 0.1M HCl. 250 
Drug solubility in each of the adsorption/dissolution media investigated are displayed in 251 
Table 4. SZ solubility in 0.1 M HCl and 0.1 M HCl with 10 mM SDS (0.3% w/v) were not 252 
significantly different. At the higher concentration of surfactant (50 mM SDS (1.44% w/v)), 253 
SZ solubility (38.80 ± 0.40 mM) was significantly higher than in the other two media (p < 254 
0.01). However, SZ solubility enhancement in the presence of both concentrations of SDS 255 
was considered marginal. 256 
3.3. Adsorption Studies  257 
3.3.1. Sulphamethazine Adsorption onto Silica in 0.1 M HCl Medium 258 
Adsorption isotherms for sulphamethazine adsorption onto SBA-15 and Aerosil®200, at the 259 
24 h time point, in 0.1M HCl at 37
o
C, are displayed in Figure 1 as both mmol SZ/g silica 260 
adsorbed and mmol SZ/m
2 
silica adsorbed. Drug adsorption onto the Aerosil®200 non-porous 261 
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surface levelled off.  In contrast, adsorption onto the mesoporous surface increased with 262 
increasing drug concentration. There was more drug bound per m
2 
to the non-porous silica 263 
surface than the mesoporous SBA-15, indicating the drug cannot access the porous network 264 
in its entirety.  265 
Adsorption data for the porous and non-porous silica systems were fitted to the Langmuir and 266 
the Freundlich adsorption models (Table 3). While both models were capable of describing 267 
the data for both silica substrates (R
2
 > 0.90), the Langmuir model emerged as the best-fit for 268 
the adsorption of SZ onto non-porous Aerosil
®
200. In contrast, drug adsorption onto 269 
mesoporous SBA-15 was best described by the Freundlich model. The Langmuir model 270 
parameters were calculated for both silica substrates. The number of binding sites on the 271 
surface (Nt (mmol/m
2
)) was determined to be greater for the non-porous Aerosil®200 than 272 
SBA-15, indicating that drug molecules cannot access the full extent of the SBA-15 porous 273 
architecture. The binding affinity (designated as a (mM)) of drug to the silica surface was 274 
equivalent for both the mesoporous material and the non-porous Aerosil
®
200 (adsorbed SZ 275 
mmol/m
2
 silica). Freundlich model parameters were also calculated for both substrates and 276 
are displayed in Table 3. The heterogeneity index (m) is defined over a range of 0 to 1 with 277 
values closer to 1 describing a more homogenous system. The non-porous material exhibited 278 
the most homogenous surface of the two materials. The Freundlich equation binding affinity 279 
parameter (Ko (mM)), revealed stronger binding affinities between the drug and the non-280 
porous surface.  281 
 282 
 283 
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 284 
Figure 1. Adsorption isotherms for SZ adsorption ((a) mmol SZ /g silica and (b) mmol SZ/m
2 
285 
silica) onto SBA-15 () and Aerosil®200 () at 24 h, 37oC in 0.1 M HCl (n=3, X and Y 286 
error bars indicate standard deviation) 287 
 288 
Table 3. Isotherm parameters obtained by fitting sulphamethazine and sodium dodecyl 289 
sulphate adsorption data (mmol/m
2
) onto SBA-15 and Aerosil®200 to Langmuir and 290 
Freundlich isotherms (SDS adsorption data only produced an acceptable fit with Freundlich 291 
isotherm). Measure of fit of data to model is indicated by the R
2 
value. 292 
SULPHAMETHAZINE 
Langmuir Isotherm Nt (mmol/m
2
) a (mM) R
2
 
SBA-15 0.04 0.0004 0.95 
Aerosil
® 0.15 0.0004 0.99 
Freundlich isotherm m Ko (mM) R
2
 
SBA-15 0.50 5.66 0.98 
Aerosil
®
 0.70 8.09 0.91 
SODIUM DODECYL SULPHATE 
Freundlich isotherm m Ko (mM) R
2
 
SBA-15 0.53 10.70 0.98 
Aerosil
®
 0.77 6.72 0.95 
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 293 
3.3.2. SDS Adsorption onto Silica in 0.1 M HCl Medium 294 
The isotherm for SDS adsorption onto both silica substrates in 0.1M HCl at 37
o
C is presented 295 
in Figure 2. The quantity of surfactant adsorbed onto both silica materials was similar in 296 
magnitude to the quantity of drug adsorbed under the same experimental conditions (Figure 1 297 
(b) versus Figure 2). For SBA-15 a correlation of r = 0.83 (p < 0.04) between surfactant and 298 
drug adsorption was determined while the correlation of adsorption on the non-porous surface 299 
was stronger at r = 0.88 (p < 0.02). The Freundlich adsorption model emerged as the best-fit 300 
model for SDS adsorption onto both substrates (R
2
 ≥ 0.95, Table 3). The Freundlich binding 301 
affinity for the surfactant with the mesoporous SBA-15 was stronger than that of the drug 302 
molecule. This is most likely a result of the surfactant’s ability to reduce interfacial tension 303 
leading to improved pore wetting and access to additional binding sites in the porous 304 
network.  305 
 306 
Figure 2. Adsorption isotherms for SDS adsorption (mmol SDS/m
2 
silica) onto SBA-15 () 307 
and Aerosil () at 24 h, 37
o
C in 0.1 M HCl (n=3, X and Y error bars indicate standard 308 
deviation) 309 
 310 
 311 
Page 16 of 33
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
17 
 
3.3.3. Sulphamethazine Adsorption onto Silica in 0.1 M HCl/SDS Media 312 
Adsorption isotherms for sulphamethazine adsorption (mmol SZ/m
2
silica) onto SBA-15 and 313 
Aerosil® at 24 h in media with 0.1 M HCl (10 mM SDS) and 0.1 M HCl (50mM SDS) at 314 
37
o
C are displayed in Figure 3. There is significantly less drug adsorbed onto both silica 315 
materials in the presence of surfactant at both SDS concentrations investigated. Similar to 316 
drug adsorption in 0.1M HCl media without surfactant (Figure 1), the non-porous Aerosil® 317 
adsorbed a larger fraction of drug/m
2
 than the mesoporous material. As this experiment 318 
involved a multi-component system where drug and surfactant are simultaneously adsorbing 319 
onto the silica surface, data was not fitted to the Freundlich and Langmuir adsorption models.  320 
 321 
 322 
Figure 3. Adsorption isotherms for SZ adsorption (mmol SZ /m
2 
silica) onto SBA-15 () and 323 
Aerosil () at 24h, 37
o
C in (a) 0.1M HCl (10mM SDS) and (b) 0.1M HCl (50mM SDS)  324 
(n=3, X and Y error bars indicate standard deviation) 325 
 326 
 327 
 328 
 329 
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3.4. Dissolution Studies 330 
Dissolution experiments were conducted in the same three media as used for adsorption 331 
experiments. Experiments were conducted under sink conditions and the theoretical SZ 332 
concentration following 100% release was < 4% the SZ solubility in all cases (Table 4).  333 
 334 
 335 
 336 
 337 
 338 
 339 
 340 
 341 
 342 
 343 
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Table 4. Solubility and dissolution parameters for unprocessed SZ and SZ loaded silica formulations in the three dissolution media investigated 345 
(mean ± standard deviation is provided, n=3) 346 
Dissolution 
Medium 
Solubility Dissolution  Dissolution (% Cumulative Release) 
Solubility of 
Drug (mM) 
% Saturated Solubility 
assuming 100% release 
Sample 5 min 10min 15 min 24 h 
0.1M HCl 30.00 ± 1.80 3.60 Unprocessed SZ 
SZ loaded SBA-15 
SZ loaded Aerosil® 
25.61±4.34 
74.03±7.21 
70.10±0.35  
51.86±5.02 
76.06±7.53 
73.47±0.83 
82.41±5.56 
74.55±6.10 
74.17±0.38 
97.26 ± 1.80 
79.58±2.08 
77.21±0.01 
0.1M HCl 
10mM SDS 
30.28 ± 0.97 3.56 Unprocessed SZ 
SZ loaded SBA-15 
SZ loaded Aerosil® 
98.65±1.04 
90.20±0.65  
89.13±4.75 
97.77±0.40 
90.27±1.06 
90.84±4.09 
97.10±0.18 
90.32±0.86 
89.08±4.41 
97.55±1.02 
92.94±1.25 
86.15±5.23 
0.1M HCl 
50 mM SDS 
38.80 ± 0.40 2.70 Unprocessed SZ 
SZ loaded SBA-15 
SZ loaded Aerosil® 
100.93±0.94 
86.97±3.15 
91.84±5.26 
100.11±0.80 
91.95±3.03 
92.84±5.27 
99.22±0.94 
94.97±6.33 
92.53±4.74 
99.71±1.06 
98.02±4.44 
90.40±4.12 
 347 
 348 
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 349 
3.4.1. Sulphamethazine/Silica Systems in 0.1 M HCl Medium 350 
Loading SZ onto porous and non-porous silica carriers significantly enhanced the drug’s 351 
dissolution rate in 0.1 M HCl buffer media compared to the unprocessed SZ (Figure 4 and 352 
Table 4). At the 5 min time point, SZ release from Aerosil
®
200 and SBA-15 was significantly 353 
higher than for the unprocessed drug. However, by 15 min, unprocessed SZ dissolution had 354 
significantly exceeded drug release from both silica systems. The amount of the free drug 355 
released remained higher for the unprocessed SZ than that of the drug/silica samples for the 356 
remainder of the experiment. At 24 h, incomplete drug release was observed for both silica 357 
systems; unprocessed SZ release was significantly greater than the extent of release from 358 
drug/silica samples (Table 4). Drug release from the porous and non-porous silica carriers 359 
was not significantly different at any of the dissolution time points.  360 
 361 
 362 
Figure 4. Dissolution profiles of SZ loaded SBA-15 (), Aerosil
®
200 (∆) and unprocessed 363 
SZ () in (a) 0.1M HCl, (b) 0.1M HCl SDS 10mM and (c) 0.1M HCl SDS 50mM (n=3, Y 364 
error bars indicate standard deviation) 365 
 366 
 367 
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3.4.2. Sulphamethazine/Silica System in 0.1 M HCl/SDS Media 368 
In vitro drug dissolution was investigated in the presence of surfactant (SDS) at the same 369 
concentrations investigated in the adsorption study (10 mM and 50 mM). The addition of the 370 
surfactant at low concentration (10 mM) significantly enhanced the rate and extent of drug 371 
release from both silica systems compared to dissolution in 0.1 M HCl media alone (Figure 4, 372 
Table 4). A further enhancement in the rate or extent of SZ release was not observed for the 373 
higher concentration of SDS (50 mM). Incomplete dissolution was observed for both porous 374 
and non-porous systems in the presence of 10 mM SDS (unprocessed drug dissolution 375 
reaches levels of 100% API release). Complete drug release was only observed for the drug/ 376 
SBA-15 samples in 0.1 M HCl containing 50mM SDS.  377 
 378 
3.5. Porosity Analysis of Recovered SBA-15 Following Dissolution  379 
Pore size distributions of unprocessed and recovered SBA-15 samples are displayed in Figure 380 
5. Changes in silica porosity can indicate a change in the quantity and distribution of bound 381 
molecules on the silica surface. A decrease in pore diameter and pore volume is evidence of 382 
the presence of drug/surfactant molecules in the pores or blocking the pores 
26
.  SBA-15 383 
samples recovered after dissolution in 0.1 M HCl displayed a reduction in mesopore volume 384 
but not mesopore width. This finding supports the hypothesis that a fraction of the drug 385 
molecules remaining is distributed on the silica surface after dissolution rather than blocking 386 
pore openings. Samples exposed to media containing surfactant displayed the greatest 387 
reduction in mesopore volume and demonstrated a significant reduction in mesopore size. 388 
This suggests that SDS molecules can adsorb onto the silica surface and have the potential to 389 
deposit in the silica mesopores and block them. 390 
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 391 
Figure 5. (a) Pore size distribution of unprocessed SBA-15 (dashed line with dot) and 392 
recovered SBA-15 samples after drug loading and dissolution in 0.1M HCl (black line), 0.1M 393 
HCl 10mM SDS (dotted line) and 0.1M HCl 50mM SDS (dashed line); 5(b) recovered SBA-394 
15 samples after drug loading and dissolution in 0.1M HCl 10 mM SDS (dotted line) and in 395 
0.1M HCl 50 mM SDS (dashed line) 396 
 397 
3.6. Relating Dissolution Release Profiles to Adsorption Isotherms 398 
The relationship between the quantity of SZ adsorbed on the silica surface at the end of the 399 
dissolution experiment and the estimated quantity of SZ adsorbed (calculated using the 400 
adsorption isotherm equations) was compared for the 0.1 M HCl media (Figure 6(a)). Figure 401 
6(a) demonstrates that the quantity of drug that remains adsorbed to the mesoporous silica 402 
surface after dissolution is significantly higher than the predicted value. The amount retained 403 
per m
2
 was considerably higher for the porous SBA-15 compared to non-porous Aerosil
®
. 404 
These results indicate that retention of drug molecules on the mesoporous silica surface was 405 
not simply due to an adsorption equilibrium between adsorbed drug and drug existing in 406 
solution in the dissolution media and that the porous architecture of silica influences the 407 
retention of drug on its surface.  408 
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In contrast to drug molecule adsorption behaviour, the quantity of SDS bound at the end of 409 
the dissolution experiment was not significantly different to the predicted values from the 410 
adsorption isotherms for the porous or non-porous systems (Figure 6 (b)).  411 
The presence of SDS significantly reduces the amount of drug retained on the silica surface at 412 
the end the of the dissolution experiment (Figure 7). This is particularly evident for the 413 
mesoporous SBA-15. It is possible that the increased wettability of the media containing the 414 
surfactant provides enhanced access to drug binding sites, resulting in less drug retention. 415 
Increasing the concentration of SDS does not result in a significant further reduction in drug 416 
retention. While the presence of surfactant increases the extent of SZ dissolution, incomplete 417 
release was observed in dissolution experiments for both silica substrates (except SBA-15 418 
loaded samples in 50mM SDS). This indicates that some drug molecules are so tightly bound 419 
to particular silica binding sites that they are, in essence, ‘irreversibly bound’ under the 420 
dissolution experimental conditions.  421 
 422 
 423 
Figure 6. Comparison of (a) SZ and (b) SDS bound both predicted (from adsorption isotherm 424 
data) and experimentally determined after dissolution in 0.1M HCl (n=3, error bars indicate 425 
standard deviation, *** denotes p < 0.001) 426 
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 427 
Figure 7. Comparison of the actual bound SZ fraction (mmol/m
2
 silica) after dissolution in the 428 
three media investigated for (a) SBA-15 and (b) Aerosil
®
 (n=3, error bars indicate standard 429 
deviation, ** denotes p < 0.01 of difference compared to amount bound in 0.1 M HCl) 430 
 431 
 432 
 433 
 434 
 435 
 436 
 437 
 438 
 439 
 440 
 441 
  442 
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5. DISCUSSION 443 
In this study, two factors demonstrated a significant influence on drug release from silica 444 
systems. The first factor was the influence of drug and surfactant adsorption onto the silica 445 
surface. The second was the ability of the dissolution medium to wet the silica surface, 446 
particularly the porous network of the mesoporous SBA-15. 447 
Drug adsorption onto the silica surface was noted for both silica materials across all three 448 
media investigated. The mesoporous material had a lower adsorbed drug fraction/m
2 449 
compared to the non-porous Aerosil®. This indicates that SZ molecules cannot access the 450 
entirety of the mesoporous network. Mesoporous silica materials have a wide range of pore 451 
sizes (between 2 – 50 nm) 
3
. It is possible that adsorbed drug molecules could block smaller 452 
pores preventing access to further drug binding sites located deeper in the porous 453 
architecture. Additionally, porous binding sites may be different in terms of the number of 454 
available sites/m
2
 and/or binding affinity to those located on the surface, resulting in altered 455 
drug adsorption levels compared to non-porous materials. Further evidence for this 456 
hypothesis is observed in the porosity analysis which displays a reduced pore volume for the 457 
drug loaded samples after dissolution in 0.1 M HCl, indicating bound drug molecules 458 
remaining are occupying mesopores on the surface. This finding is interesting as it suggests 459 
accessible surface area rather than specific surface area of the SBA-15 is as an important 460 
parameter in drug loading and dissolution from these porous systems. Future studies should 461 
examine the influence of mesoporous materials with different porous architectures on drug 462 
adsorption and release from these formulations. 463 
Adsorption isotherms for single component systems were fitted to the Langmuir and 464 
Freundlich linearized equations. These two models have also been used successfully in other 465 
studies investigating adsorption on silica substrates 
16, 27, 28
. The Langmuir model describes a 466 
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homogeneous surface which contains only one type of binding site 
29
. It emerged as the best-467 
fit for drug binding onto the non-porous Aerosil®. In contrast, SZ adsorption onto 468 
mesoporous SBA-15 produced a Freundlich model best-fit correlation. The Freundlich model 469 
is an empirical model which describes a heterogeneous surface (a system which contains a 470 
range of binding sites with different binding affinities) and indicates that multi-layer 471 
adsorption of drug onto the porous SBA-15 surface exists 
30
. This observation agreed with a 472 
previous literature report which demonstrated that the Freundlich isotherm proved the best-fit 473 
for the absorption of a range of pharmaceuticals onto SBA-15 
16
. The number of SZ binding 474 
sites on the surface (Nt) was lower for the mesoporous material. This is further evidence that 475 
the accessible surface area of the porous silica is an important parameter to consider for these 476 
formulations. The binding affinity (designated as a for the Langmuir isotherm and Ko for the 477 
Freundlich model) of drug to the surface is stronger for the non-porous Aerosil®. This is most 478 
likely a result of SBA-15’s porous architecture as drug interactions with the surface could 479 
vary depending on the dimensions of the pores and silica surface chemistry.   480 
The quantity of surfactant adsorbed onto both silica substrates was significantly similar in 481 
magnitude to the quantity of drug adsorbed under the same experimental conditions and 482 
concentration range (from adsorption isotherms, Figure 1(b) and Figure 2). This was 483 
determined by correlating drug and surfactant adsorption onto both silica surfaces (Section 484 
3.3.2). Both molecules have a similar molecular mass (278.33g/mol for SZ and 288.372g/mol 485 
for SDS). SDS is an anionic surfactant and SZ has an aromatic amine functional group with a 486 
pKa of 2.06 ± 0.30. The isoelectric point of the silica surface has been measured as pH 2 
31
. In 487 
0.1M HCl, the results indicate that the more positively charged silica has a similar potential 488 
to attract both surfactant and drug molecules. Drug interaction with the silica surface is most 489 
likely a result of hydrogen bonding between the aromatic amine functional group and the 490 
silanol hydroxyl groups. Amine-silanol hydrogen bonding between drug molecules and the 491 
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silica surface has been reported previously in a study by Xue et al 
17
. The interaction of the 492 
surfactant with the silica surface is not well understood. In this case, it is likely that the 493 
negatively charged head group interacts with the silica surface (which is slightly positively 494 
charged under these experimental conditions). It is possible that the SDS molecules adsorb in 495 
a multilayer hemi-micelle formation. This phenomenon has been described for cationic 496 
surfactant adsorption at the silica gel – water interface 
32
. The nature of this surfactant – silica 497 
interaction requires further investigation.  498 
The results of this study indicate that the retention of drug molecules on the mesoporous 499 
silica surface is not simply due to an equilibrium adsorption related to the concentration of 500 
drug in solution in the dissolution media. A certain fraction of the loaded drug molecules are 501 
bound very tightly or to sites which are inaccessible for the dissolution media. These findings 502 
reinforce the influence of the porous network in drug dissolution from these systems. While 503 
the quantity of loaded drug retained at the end of dissolution was greater than the predicted 504 
quantity, the amount of surfactant adsorbed was not significantly different when predicted 505 
and experimental values were compared. The surfactant was not loaded onto the silica 506 
material in the dissolution experiment. This observation indicates that the drug loading 507 
process utilised in this study (SC-CO2 loading) is another factor to consider in determining 508 
drug adsorption/release behaviour. It has been reported in the literature that water molecules 509 
can adsorb onto silica by interacting with surface functional groups 
33
. It is possible that 510 
during drug loading under SC-CO2 conditions, water that was bound to the silica surface was 511 
removed thus activating potential binding sites which would otherwise be unavailable in the 512 
mesoporous material. This could increase the bound drug fraction remaining at the end of 513 
dissolution as drug molecules are potentially more difficult to remove from these binding 514 
sites.  515 
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While both concentrations of SDS investigated were determined to be above the surfactant 516 
CMC in 0.1M HCl (0.8mM), drug solubility was only marginally enhanced in the dissolution 517 
media containing 50mM SDS. This is most likely due to the extent of incorporation of SZ (an 518 
acidic drug) into surfactant micelles which is dependent on the pKa (acid dissociation 519 
constant) of the drug and the ionic nature of the surfactant 
34
. As the pKa of the aromatic 520 
amine (2.06 ± 0.30) is only marginally above the pH, it is possible the drug is not fully 521 
protonated, reducing drug partitioning into anionic SDS micelles.  522 
However, despite the marginal improvement in drug solubility, the addition of surfactant at 523 
both concentrations (10 mM and 50 mM) significantly enhanced the rate and extent of drug 524 
release from both porous and non-porous systems compared to dissolution in 0.1 M HCl 525 
alone. In this case, the improved wetting characteristics of the media in the presence of the 526 
surfactant is the most likely explanation for the improved dissolution profile. Surfactants 527 
decrease the solid/liquid surface tension 
35
 which could allow the dissolution media to access 528 
additional drug binding sites thus enhancing drug release. Superior release was observed for 529 
the non-porous Aerosil® at 1 min compared to SBA-15. This could be attributed to the time 530 
taken for the media to wet the pores. At 5 min, there is no significant difference in the extent 531 
of release between the two silica systems. This remains the case for the remainder of the 532 
experiment (24 h).  533 
 534 
 535 
 536 
 537 
 538 
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6. CONCLUSIONS 540 
This study demonstrates that drug adsorption plays a role in the release of drug molecules 541 
from drug/silica systems. Adsorption isotherms proved useful for understanding drug release 542 
for non-porous silica formulations. However, adsorption behaviour does not explain the high 543 
quantity of drug retained on mesoporous formulations. The addition of sodium dodecyl 544 
sulphate to the dissolution media was shown to have a significant impact on sulphamethazine 545 
dissolution from both porous and non-porous silica systems. The study findings highlight the 546 
importance of considering drug and dissolution media interaction with the silica substrate and 547 
accessibility of dissolution media to the silica porous architecture when optimising drug 548 
release from drug/silica systems. 549 
 550 
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